Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Flouvat

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Archives Des Maladies Du Coeur Et Des Vaisseaux|June 1, 1981
[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]M Chaignon, E Le Roux, P Aubert, et al.
European Journal of Clinical Pharmacology|January 1, 1993
Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severityB Delhotal-Landes, B Flouvat, J Duchier, et al.
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1991
The effect of food and antacids on lansoprazole absorption and dispositionB Delhotal-Landes, A Cournot, N Vermerie, et al.
Journal De Pharmacologie|July 1, 1985
Hemodynamic effects of a new antiarrhythmic agent: cibenzolineM Rigaud, G Jouret, M Canal, et al.
Archives Francaises De Pediatrie|May 1, 1991
[Pharmacokinetics of aspirin in African children with normal nutrition and malnutrition]J M Treluyer, E Sultan, J A Alexandre, et al.
Acquisitions Medicales Recentes|January 1, 1977
[Study of the binding of beta blockers to plasma proteins. Therapeutic consequences]S Decourt, A Roux, A Baglin, et al.
British Journal of Clinical Pharmacology|April 1, 1980
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysisB Flouvat, S Decourt, P Aubert, et al.
British Journal of Clinical Pharmacology|April 1, 1982
Antihypertensive effect of diacetolol in essential hypertensionM Thibonnier, C Flabeau, M Thouvenin, et al.
Therapie|May 1, 1979
[Protein binding and elimination half-life of furosemide in chronic hemodialysed patients]S Decourt, B Flouvat, A Goupil, et al.
British Journal of Clinical Pharmacology|May 1, 1989
Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjectsB Flouvat, I Berlin, A Cournot, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Archives Des Maladies Du Coeur Et Des Vaisseaux|June 1, 1981
[Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]M Chaignon, E Le Roux, P Aubert, et al.
European Journal of Clinical Pharmacology|January 1, 1993
Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severityB Delhotal-Landes, B Flouvat, J Duchier, et al.
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1991
The effect of food and antacids on lansoprazole absorption and dispositionB Delhotal-Landes, A Cournot, N Vermerie, et al.
Journal De Pharmacologie|July 1, 1985
Hemodynamic effects of a new antiarrhythmic agent: cibenzolineM Rigaud, G Jouret, M Canal, et al.
Archives Francaises De Pediatrie|May 1, 1991
[Pharmacokinetics of aspirin in African children with normal nutrition and malnutrition]J M Treluyer, E Sultan, J A Alexandre, et al.
Acquisitions Medicales Recentes|January 1, 1977
[Study of the binding of beta blockers to plasma proteins. Therapeutic consequences]S Decourt, A Roux, A Baglin, et al.
British Journal of Clinical Pharmacology|April 1, 1980
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysisB Flouvat, S Decourt, P Aubert, et al.
British Journal of Clinical Pharmacology|April 1, 1982
Antihypertensive effect of diacetolol in essential hypertensionM Thibonnier, C Flabeau, M Thouvenin, et al.
Therapie|May 1, 1979
[Protein binding and elimination half-life of furosemide in chronic hemodialysed patients]S Decourt, B Flouvat, A Goupil, et al.
British Journal of Clinical Pharmacology|May 1, 1989
Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjectsB Flouvat, I Berlin, A Cournot, et al.
Pageof 10